CJC-1295 + Tesamorelin: the stack guide
CJC-1295 and Tesamorelin are both GHRH analogs — stacking them is unusual, since they activate the same receptor. The pairing is occasionally discussed for combining CJC-1295's long half-life with Tesamorelin's clinical visceral-fat data, but the case for running both simultaneously is weaker than for GHRH + GHRP combinations.
Why CJC-1295 and Tesamorelin pair well
CJC-1295 (with DAC) has a multi-day half-life and sustains baseline GHRH signaling. Tesamorelin has a shorter half-life but robust clinical data for visceral fat reduction. Running them together doesn't synergize pharmacologically — it stacks overlapping receptor agonism, which can desensitize the GHRH receptor faster than either alone. Most practitioners choose one or the other rather than combining.
Suggested cadence
If run together despite the redundancy, the common approach is low-dose CJC-1295 (50–100 mcg twice weekly) with standard Tesamorelin (1–2 mg daily). Cycles are typically limited to 8–12 weeks followed by a ≥4-week washout to restore receptor sensitivity. A more evidence-aligned alternative is pairing either GHRH with a GHRP like ipamorelin.
This is informational only — dosing should always be individualized and discussed with a qualified clinician.
Reconstitution notes
CJC-1295: A common ratio is 2 ml of bacteriostatic water for a 2 mg vial. Open the CJC-1295 calculator →
Tesamorelin: A common ratio is 2 ml of bacteriostatic water for a 5 mg vial. Open the Tesamorelin calculator →
Side effects to watch for
Receptor desensitization shows up as diminished IGF-1 response over 4–6 weeks. Sustained water retention, joint stiffness, and elevated fasting glucose are more likely with overlapping GHRH agonism than with a GHRH/GHRP split. If IGF-1 stops rising on repeat labs, the stack is doing less than monotherapy.
The two compounds
Track this stack on iPhone
Peptide Protocol schedules both compounds, calculates reconstitution, and rotates injection sites automatically.
See the app →Frequently asked questions
Why stack CJC-1295 with Tesamorelin?
CJC-1295 and Tesamorelin are both GHRH analogs — stacking them is unusual, since they activate the same receptor. The pairing is occasionally discussed for combining CJC-1295's long half-life with Tesamorelin's clinical visceral-fat data, but the case for running both simultaneously is weaker than for GHRH + GHRP combinations.
What is the typical CJC-1295 + Tesamorelin dose?
If run together despite the redundancy, the common approach is low-dose CJC-1295 (50–100 mcg twice weekly) with standard Tesamorelin (1–2 mg daily). Cycles are typically limited to 8–12 weeks followed by a ≥4-week washout to restore receptor sensitivity. A more evidence-aligned alternative is pairing either GHRH with a GHRP like ipamorelin.
Can you inject CJC-1295 and Tesamorelin in the same syringe?
Many users co-administer GHRH + GHRP pairs (like CJC-1295 + Ipamorelin) in a single syringe to reduce injections, since both are stable in bacteriostatic water for short periods. For other pairs, draw and inject separately to minimize compatibility risk and to attribute any reaction to the correct compound.
What side effects should I watch for?
Receptor desensitization shows up as diminished IGF-1 response over 4–6 weeks. Sustained water retention, joint stiffness, and elevated fasting glucose are more likely with overlapping GHRH agonism than with a GHRH/GHRP split. If IGF-1 stops rising on repeat labs, the stack is doing less than monotherapy.
How long should a CJC-1295 + Tesamorelin cycle run?
Most user-reported cycles run 4–12 weeks depending on the goal. GH-axis stacks are typically cycled with a break of 4 weeks or more between blocks to preserve receptor sensitivity. Soft-tissue stacks are usually run continuously until the injury resolves.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.